Trial Profile
A Multi-Center, Open-Label, Single Administration, Sequential Dose Escalation of BIW-8405/MEDI-563 in Subjects With Mild Asthma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Mar 2019
Price :
$35
*
At a glance
- Drugs Benralizumab (Primary)
- Indications Asthma
- Focus Adverse reactions
- 11 Mar 2019 Results assessing pharmacokinetic (PK) data from nine clinical trials (NCT00512486, NCT00659659, NCT00768079, NCT00783289, NCT01238861, NCT01928771, NCT01914757, NCT02322775, NCT02075255) for patients with asthma, published in the Clinical Pharmacokinetics.
- 26 Nov 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Oct 2008 Interim results were reported at the European Respiratory Society meeting.